Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCryofocus-B
Stock Code06922
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities主要專注於微創介入冷凍治療領域,核心產品為膀胱冷凍消融系統及內鏡吻合夾,產品組合覆蓋經自然腔道內鏡手術(治療泌尿、呼吸及消化系統疾病)及血管介入療法(治療房顫、高血壓等心血管疾病)。
Listing Date2022-12-30
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區康新公路3399弄15號樓
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.cryofocus.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 18.90 / shares
Offer Price RangeTo be extracted
Lot Size200 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2022-12-16 to 2022-12-21
Global Offering Shares11,110,000 shares
HK Public Offer Shares (Initial)1,111,000 shares (10.0%)
Public Offer Lots (Initial)5,555lots (Pool A2,777lots,Pool B2,778lots)
International Placing Shares (Initial)9,999,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO239,110,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 209,979,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
0 lots 5 HK$ 0
0 lots 10 HK$ 0
0 lots 20 HK$ 0
0 lots 25 HK$ 0
1 lots 200 HK$ 0
2 lots 400 HK$ 0
3 lots 600 HK$ 0
4 lots 800 HK$ 0
5 lots 1,000 HK$ 0
6 lots 1,200 HK$ 0
7 lots 1,400 HK$ 0
8 lots 1,600 HK$ 0
9 lots 1,800 HK$ 0
10 lots 2,000 HK$ 0
15 lots 3,000 HK$ 0
20 lots 4,000 HK$ 0
25 lots 5,000 HK$ 0
30 lots 6,000 HK$ 0
35 lots 7,000 HK$ 0
40 lots 8,000 HK$ 0
50 lots 10,000 HK$ 0
75 lots 15,000 HK$ 0
100 lots 20,000 HK$ 0
125 lots 25,000 HK$ 0
150 lots 30,000 HK$ 0
250 lots 50,000 HK$ 0
300 lots 60,000 HK$ 0
400 lots 80,000 HK$ 0
500 lots 100,000 HK$ 0
1,000 lots 200,000 HK$ 0
1,250 lots 250,000 HK$ 0
29,590 lots 5,918,000 HK$ 0

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 610.2M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1492%

Valuation & Financials

Market Cap (at Offer Price)HK$ 4,519,179,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣126.5百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 70,079,000
Listing Expenses / Funds Raised~33.37%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2020
Revenue 9,054
Cost of sales -4,414
Gross profit 4,640
Other income and gains, net 5,283
Selling and distribution expenses -43,000
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 17.66
First Day OpenHK$ 18.5
First Day Change-6.56%
First Day Volume771400.0
First Day Turnover14154600.0
Use of Proceeds
1、58.2%或約81.4百萬港元將用于為膀胱冷凍消融系統的研發活動、商業推廣(包括銷售及營銷)及制造提供資金; 2、15.7%或約22.0百萬港元將用于為內鏡吻合夾的研發活動、商業推廣(包括銷售及營銷)及制造提供資金; 3、6.1%或約8.5百萬港元將分配予心臟冷凍消融系統的研發活動、計劃商業推廣及制造; 4、20.0%或約28.0百萬港元將分配予目前產品管線的其余14款在研產品的研發活動、注冊備案、計劃商業推廣及制造。

Underwriting Syndicate

Joint Sponsors (2)
Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (4)
Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 农银国际证券有限公司 CE ACX411
Joint Bookrunners (7)
Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 农银国际证券有限公司 CE ACX411 交银国际证券有限公司 CE APJ121 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (8)
Citigroup Global Markets Asia Limited CE AAA137 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 农银国际证券有限公司 CE ACX411 交银国际证券有限公司 CE APJ121 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940 SILVERBRICKS SECURITIES COMPANY LIMITED CE BLN458

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman李克儉—
Company Secretary劉偉、梁慧欣—
No director data available.

Major Shareholders

Major Shareholders & Holdings李女士及呂先生(一致行動人士)緊隨全球發售完成後合共持有約55.60%股份,寧波麟灃及上海仕地為其控制法團;珠海高瓴鈞恒持股約5.66%;蘇州新建元二期創投持股約5.14%。
About this page

This page shows Cryofocus-B (06922) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect